EMI-137 in laparoscopic colonic resections is a single-centre stage IIa developmental study.
Ten adult participants with a diagnosis of colon adenocarcinoma undergoing laparoscopic
colonic will be recruited to the trial. Participants will receive a single intravenous dose
of the IMP - EMI-137 1 to 3 hours before surgery. The ability of EMI-137 to produce visible
intra-operative fluorescence of primary colon cancer and lymph node metastases will be
explored and evaluated.